Legend Biotech Corporation has announced promising interim results from a Phase 1 study of LB2102, a DLL3-targeted CAR-T cell therapy, in patients with lung cancers. The study, presented at a recent conference, involved patients with relapsed or refractory small-cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) who had received at least one prior line of therapy. The results indicated that LB2102 was well tolerated, with no dose-limiting toxicities observed up to Dose Level 4. The study also showed encouraging signs of dose-dependent efficacy, with clinical responses correlating with CAR-T cell expansion. These findings support continued dose escalation and further clinical evaluation. Legend Biotech is conducting this study in the U.S. under an exclusive global license agreement with Novartis Pharma AG.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。